SectorBiological Technology
Established Date22/10/2018
Listing Date18/02/2022
ExchangeNASDAQ Stock Exchange
Full-time Employees2
Fiscal Year Ends31/12
Security TypeCommon stock
Office address201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202
Business
IntroductionOnconetix, Inc., was incorporated in Delaware on October 22, 2018. The Company is a commercial-stage biotechnology company focused on the research, development and commercialization of oncology proprietary therapies, diagnostics and services for clinicians and patients. The company currently owns EntadFi, an FDA-approved oral treatment for benign prostatic hyperplasia (BPH), a prostate disease, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosing men with indeterminate prostate-specific antigen (PSA) assessment in prostate cancer oncology.
